With this purchase you will earn points for subsequent purchases
Free shipping on orders over 39.00€
Fill in your email and you will be informed as soon as we receive the product
The first probiotic in drops worldwide (2004). Clinically studied and proven as a dietary treatment for the treatment of 1st trimester colic in infants.
Dosage: 5 drops once daily (contain 108 CFUs L.reuteri ProTectis®). Each vial lasts for one month.
Suitable for the prevention of gastrointestinal disorders from antibiotics (diarrhea, abdominal pain, flatulence) in infants and toddlers.
Dosage: 5 drops once (contain 108 CFUs L.reuteri ProTectis®) 1 hour after administration of the antibiotic. Each vial is sufficient depending on the antibiotic administration per 24 hours.
Suitable for the treatment of gastrointestinal disorders from antibiotics (diarrhea, abdominal pain, flatulence) in infants and toddlers.
Dosage: 10 drops once (contain 2x108 CFUs L.reuteri ProTectis®) 1 hour after each antibiotic administration. Each vial is sufficient depending on the antibiotic administration per 24 hours.
It is also recommended for the prevention of functional gastrointestinal disorders (colic, constipation, regurgitation) in infants during the first 6 months of life. Dosage: 5 drops once a day (contain 108 CFUs L.reuteri ProTectis®) for the period of the first three months. Each vial lasts for one month.
Absolutely safe for babies, toddlers and children
Clinically proven to reduce colic in infants
Clinically proven to prevent gastrointestinal upset from antibiotics
Clinically proven to prevent functional gastrointestinal disorders
Easy to administer to infants and children
It does not affect breastfeeding or the taste of foods
The probiotic L.reuteri Protectis®
BioGaia® ProTectis drops contain L.reuteri Protectis®, the certified probiotic bacterium of the Swedish company BioGaia. Originally isolated from breast milk, it is one of the most studied probiotics in the world and the most studied in infants and children. Its safety and effectiveness have been proven in 108 clinical studies (last update 12/2014).
L.reuteri Protectis® fully meets the requirements of the WHO. for probiotics. An in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a five-day period showed that L. reuteri Protectis® was one of only three surviving strains.
This fact was confirmed in vivo, when taken by healthy people led to significant colonization of the stomach, duodenum and ileum.
L. reuteri Protectis® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.
Indicative clinical trials in infantile colic with the probiotic L.reuteri Protectis®
An open-label study published in the journal Pediatrics by Savino (2007) demonstrated the efficacy of L.reuteri Protectis® over simethicone:
74% reduced crying time with L. reuteri Protectis® compared to
26% reduction with the chemical simethicone
A study published in the journal Pediatrics by Savino (2010) demonstrated the efficacy of L.reuteri Protectis® in relation to placebo:
74% reduced crying time with L. reuteri Protectis® compared to
38% reduction with placebo after one week of treatment
An independent study published in the journal Pediatrics by Szajewska (2012) confirmed the efficacy of L.reuteri Protectis® in relation to placebo:
75% success in treatment within two weeks with L. reuteri Protectis® compared to
18% in the placebo group
Significantly improved family quality of life in the L. reuteri Protectis® group
A new, independent study published in the journal JAMA Pediatrics by Indrio (2014) confirmed the possibility of preventing functional gastrointestinal disorders in the first trimester of life with L.reuteri Protectis® compared to placebo.
EAN: 7330934081008, 7350012551148
